

7:30 Breakfast	
8:00 Opening Session	
Welcome	Steven Young (President & CEO) Jonathan Fletcher MD (CSO)
Ars longa, vita brevis: accelerating translation and collaboration to develop effective new therapies for sarcoma patients	George Demetri MD Division Chief – Sarcoma Center Senior VP for Experimental Therapeutics Co-Director, Ludwig Center Dana-Farber/Harvard Cancer Center
Q&A	
8:45 SARC Symposium	
Introduction	Co-Moderators: Sandra D’Angelo MD (MSKCC) Seth Pollack MD (Northwestern U.)
Emerging Checkpoints in Sarcoma	Breelyn Wilky MD (U. of Colorado Cancer Center)
Targeting fusions in sarcoma with T cell therapy	Lauren Banks MD, PhD (MSKCC)
CAR T Cell Therapy in Sarcoma	Navin Pinto MD (U. of Washington, Seattle Children’s Hospital)
Q&A/Panel Discussion	Speakers & Co-Moderators
10:15 Break (10 minutes)	
10:25 SARC Accelerator Project and Career Development Award Recipients	
Accelerator Project 2022 SARC Career Award Q&A	Joanna Przybyl PhD (McGill U.) Lillian Guenther MD, PhD (DFCI / St. Jude Children’s Research Hospital)
10:50 SARC Trials: Currently Enrolling	
Introduction	Presenter (bolded) Scott Okuno MD (Medical Officer)
SARC031 Phase 2 MEK Inhibitor Selumetinib with Dual mTOR Kinase Inhibitor Sirolimus in MPNST	AeRang Kim MD, PhD (PI) Brigitte Widemann MD (co-PI)
SARC032 Phase 2 Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Soft Tissue Sarcoma of the Extremity	David Kirsch MD, PhD (PI) Yvonne Mowery MD, PhD (co-I)
SARC033 Phase 2 Trametinib in Unresectable or Metastatic Epithelioid Hemangioendothelioma	Scott Schuetze MD (PI) Libby Davis MD (co-I)
SARC037 Phase I Trabectedin in Ewing Sarcoma in Combination with Irinotecan and 18F-FLT Imaging	Patrick Grohar MD, PhD (PI)
SARC038 Phase 2 Regorafenib in Combination with Nivolumab in Osteosarcoma	Fariba Navid MD (PI) Lara Davis MD (co-PI)
SARC041 Phase 3 Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS	Mark Dickson MD (PI)
Q&A/Panel Discussion	Speakers & SARC Medical Officer
11:35 SARC Mission & Evolution	
Committees & Initiatives Accelerator Program Closing Comments	Jonathan Fletcher MD (CSO) Keila Torres MD, PhD (MDACC) Steven Young (President & CEO)
12:00 Adjourn	